Effects of anti-β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity.

ABSTRACT:

Background

Antiphospholipid syndrome (APS) is characterized by recurrent thromboembolic events in the setting of pathologic autoantibodies, some of which are directed to β2-Glycoprotein 1 (β2GPI). The mechanisms of thrombosis in APS appear to be multifactorial and likely include a component of endothelial activation. Among other things, activated endothelium secretes von Willebrand factor, a hemostatic protein that in excess can increase the risk of thrombosis.

Objective

We hypothesized that anti-β2GPI antibodies could regulate the release and modulation of VWF from endothelial cells.

Patients/methods

Isolated anti-β2GPI antibodies from patients with APS were assayed for their ability to induced VWF release from HUVECs and modulate the effects of ADAMTS13 in a shear-d

SUBMITTER: Ng CJ 

PROVIDER: S-EPMC5974922 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature